Travere Therapeutics, Inc. (TVTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$66.22+0.23%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Travere grows revenue to $500M-$550M in 2026. FILSPARI helps 100,000 patients. The Everest deal adds new growth chances. Revenue rose 12.8% from 2025-Q2 to 2026-Q1.
Revenue fell slightly from 2025-Q4 to 2026-Q1. The company still loses money. Everest partnership progress is uncertain.
The price is about 17% above our fair value near $49. Analysts expect 49% revenue growth. Our fair value is below the Street median of $59.5.
Breaks if: Everest partnership fails or stalls in 2026
Leverage the exclusive license and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector, particularly focused on rare kidney diseases. The current thesis state is intact, but it faces volatility due to recent earnings performance and management changes.
The market currently prices TVTX as relatively cheap compared to its peers, with a notable expectations gap. This suggests that investors may not be fully factoring in the company's potential growth from expanding its product offerings.
Fundamentals are likely to show mixed results in the near term due to the company's loss-making status and elevated risk. Recent financial performance has been neutral, and management is focused on expanding market reach and advancing key studies, though there is a significant probability of missing earnings expectations.
The thesis hinges on several factors, including the success of the FILSPARI market expansion and the outcomes of the Phase 3 HARMONY Study. Additionally, broader healthcare sector performance and macroeconomic conditions, such as job growth, will play a critical role in shaping investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Total revenue falls below $490 million in FY26
Drive continued commercial momentum for FILSPARI including growth in IgAN and launch in FSGS, expanding patient access and sales.
Stated as a priority in 3 of last 3 quarters. U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million in 2026-Q2 from $71.8 million in 2025-Q2, with six-month sales up 93% to $246.2 million. Total product sales rose from $94.8 million in 2025-Q2 to $161.4 million in 2026-Q2. Management has consistently emphasized expanding FILSPARI's market reach including the FSGS launch and IgAN growth, and the financials show delivering strong commercial momentum.
“Continued commercial momentum for FILSPARI, including a promising early launch in FSGS and continued strength in IgA nephropathy.”
“We remain focused on execution and on expanding our impact for people living with rare disease.”
“Total revenue 129,689 74,787 490,728 233,175 supporting growth opportunity.”
Breaks if: Revenue falls below $490 million in FY26
In summary, TVTX's long-term outlook is supported by its growth initiatives, but it faces risks from market volatility and execution challenges. Not investment advice.